| abstract |
The present invention relates to a histone deacetylase (HDAC) inhibitor represented by chemical formula 1 that enables reactivation of HIV-1 proviruses from latently HIV-infected cells, and a method for reactivating HIV-1 provirus from latently HIV-infected cells using the inhibitor. The HDAC inhibitor exhibits low cytotoxicity and high stability, and thus can effectively reactivate latent HIV-1 proviruses from a CD4+ T cell reservoir. Accordingly, the HDAC inhibitor is processed together with an HAART cocktail therapeutic drug such as a reverse transcriptase inhibitor AZT, thereby efficiently reducing or removing the latent HIV reservoir. |